Aging Population and Unhealthy Foods Habits to Boost the Sales of Radiopharmaceuticals

0


A radiopharmaceutical is a radioactive compound or drug, used for the diagnosis and therapeutic treatment of human diseases. Gallium Citrate Ga 67, Sodium Fluoride F 18, Technetium Tc 99m Disofenin, Indium In 111 Pentetreotide, Technetium Tc 99m Arcitumomab are some examples of the radiopharmaceutical. Radiopharmaceutical has two components; radionuclide and pharmaceutical. It is a compound manufactured for use as a medicinal drug, for instance, Prozac. They can be inserted into a vein, taken by mouth or placed in a body cavity. These are used in various diseases like blood volume studies, abscess & infection, blood vessel diseases of the brain, bone diseases and biliary tract blockage etc. Radiopharmaceuticals can be divided into four categories, are radiopharmaceutical preparation, radionuclide generator, radiopharmaceutical precursor and kit for radiopharmaceutical preparation. A radiopharmaceutical preparation is a medicinal product, suitable for human use which contains a radionuclide, used for one or more diagnostic or therapeutic applications.

According to study, “Global Radiopharmaceutical Market Research Report – Forecast To 2023” some of the companies that are working in radiopharmaceutical are Bicron, ANSTO, Capintec, Dupoint, CORPUS, BC technical Inc., Digirad, IZOTOP, GE healthcare, MEDASYS, Inderlec medical systems, Pharmex, Nuclide navigator lite, SMV nuclear medicine company, Segami, international, Schiller America, Toshiba medical system,

Radiopharmaceutical dispensing recommends dosage level based on patient history, age, weight and surface area etc. Dispensing also develops policies & procedures to ensure that the correct drug in the correct dosage & dosage form is received by the correct patient at the correct time by a correct route of administration. Whereas distribution of it complies with all applicable regulations concerning packaging, labeling & transportation of radioactive and other materials.

The advantages of radiopharmaceutical include diagnosis and treatment of a patient, availability of modes, provide fast onset of pain relief, single dose effect, cost-effective and no side effect etc. There are some disadvantages of radiopharmaceutical such as radiation risk, allergic reaction, prolonged inconvenience &discomfort, occurring myelosuppression etc.

Radiopharmaceutical market is segmented in various terms. On the basis of application, the market is segmented into cardiology, oncology, neurology, and thyroid. On the basis of modality, a market is segmented into PET, alpha-emitters, beta-emitters, SPECT, and brachytherapy. On the basis of type, a market is segmented into diagnostic and therapeutic. On the basis of end-user, the market is segmented into hospitals & diagnostic centers and research institutes. On the basis of the type of test, the market is segmented into lung scan, bone scan, gallium scan, white blood cell scan, renal nuclear scan, parathyroid scans, and hepatobiliary scans. On the basis of the route of administration, the market is segmented into intravenous and intravitreal.

The global radiopharmaceutical market was valued at US$5.2 billion in 2017 and is estimated to reach US$7.4 billion by 2024, expanding at a CAGR of 5.4% from 2017 to 2024. North America is the most attractive regional market in the global radiopharmaceuticals market. The growth in the region is expected to continue with the technological improvements in PET scanning devices. The other factor impacting the global radiopharmaceuticals market is the rising prevalence of cancer. This has significantly increased the number of nuclear medicine procedures performed in the region and is on the specific reason that the market for radiopharmaceuticals is steadily growing in North America. There have been a rising number of cardiovascular diseases among the people in North America due to the aging population, unhealthy food habits and rising obesity. The increasing number of cardiovascular patients is expected to boost the sales of radiopharmaceuticals, which would eventually create growth in the global radiopharmaceuticals market.

To know more, click on the link below:

Global Radiopharmaceutical Market Research Report – Forecast To 2023

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91-9015378249

Share.

Comments are closed.